Aptamers Market Report by Type (Nucleic Acid, Peptide), Application (Diagnostics, Therapeutics, Research and Developments, and Others), and Region 2024-2032
세계의 압타머 시장 규모는 2023년 26억 달러에 달했습니다. IMARC Group은 향후 시장이 2032년까지 118억 달러에 이를 전망이며, 2024년부터 2032년까지 17.8%의 성장률(CAGR)을 나타낼 것으로 예측했습니다.
압타머는 단백질, 펩티드, 탄수화물, 저분자, 독소, 살아있는 세포 등 특정 대상에 결합하는 다목적 올리고뉴클레오티드입니다. 올리고뉴클레오티드는 변형가능하며, 면역원성이 없고, 감도가 높고, 독성이 낮고, 제조가 용이하며, 저분자량이며, 항체와 비교하여 제조의 차이로 인한 변동이 없습니다. 그 결과 치료 및 생명 공학 분야에서 널리 사용됩니다. 또한 연구용 약제, 진단제, 바이오센서, 바이오마커 및 창약 도구로도 세계에서 이용되고 있습니다.
세계의 압타머 시장 동향
암, 신경 퇴행성 질환, 심혈관 질환 및 후천성 면역 결핍 증후군(AIDS)과 같은 생명을 위협하는 질병의 확산이 확대되고 있는 것은 압타머 치료별 신규하고 효과적인 검출 분석 수요에 영향을 미치는 중요한 요인 중 하나입니다. 게다가, 뉴클레아제 내성을 높이고 압타머의 치료 특성을 향상시키는 화학적 변형 과정의 출현이 시장 성장을 뒷받침하고 있습니다. 압타머 시장의 성장은 진단기기 및 의약품, 그 경력을 개량하기 위해서 행해지는 연구개발(R&D) 활동 증가에도 기인하고 있습니다. 이와는 별도로, 압타머는 화학적으로 합성되기 때문에 배치간의 편차가 없고 개발에 소요되는 시간이 짧기 때문에 그 응용은 전 세계적으로 널리 확대되고 있습니다. 게다가 민간기업은 학술기관이나 연구소와 협력하여 차세대 제품을 도입하여 기존 시장의 존재를 확대하려고 합니다. 이러한 이유로 광범위한 의료 요법과 식음료(F&B) 업계에서 압타머의 이용이 촉진될 것으로 예상됩니다.
이 보고서에서 다루는 주요 질문
- 세계의 압타머 시장은 지금까지 어떻게 추이하고 향후 어떻게 추이할 것인가?
- COVID-19는 세계의 압타머 시장에 어떤 영향을 미쳤는가?
- 주요 지역 시장은?
- 유형별 시장 내역은?
- 용도별 시장 내역은?
- 업계 밸류체인의 다양한 단계란?
- 업계의 주요 촉진요인 및 과제는 무엇인가?
- 세계 압타머 시장의 구조 및 주요 진출기업은?
- 업계 경쟁도는?
목차
제1장 서문
제2장 조사 범위 및 조사 방법
- 조사의 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 서문
제5장 세계의 압타머 시장
- 시장 개요
- 시장 실적
- COVID-19의 영향
- 시장 예측
제6장 시장 내역 : 유형별
제7장 시장 내역 : 용도별
제8장 시장 내역 : 지역별
- 북미
- 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 라틴아메리카
- 중동 및 아프리카
제9장 SWOT 분석
제10장 밸류체인 분석
제11장 Porter's Five Forces 분석
- 개요
- 구매자의 협상력
- 공급기업의 협상력
- 경쟁도
- 신규 참가업체의 위협
- 대체품의 위협
제12장 가격 분석
제13장 경쟁 구도
- 시장 구조
- 주요 기업
- 주요 기업 프로파일
- Aptagen LLC
- Aptamer Group
- Aptamer Sciences Inc.
- Aptus Biotech SL
- Base Pair Biotechnologies Inc.
- IBA GmbH
- Kaneka Eurogentec SA(Kaneka Corporation)
- NeoVentures Biotechnology Inc.
- NOXXON Pharma
- SomaLogic Inc.
- TriLink BioTechnologies LLC
- Vivonics Inc.
AJY
The global aptamers market size reached US$ 2.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 11.8 Billion by 2032, exhibiting a growth rate (CAGR) of 17.8% during 2024-2032.
Aptamers are versatile oligonucleotides that bind to a specific target, including proteins, peptides, carbohydrates, small molecules, toxins, and live cells. They are modifiable, nonimmunogenic, highly sensitive, less toxic, easy to prepare and have low molecular weight and no variation with different preparations as compared to antibodies. As a result, they are widely being used in therapeutic and biotechnological applications. Besides this, they are also utilized as research agents, diagnostics, biosensors, and tools for biomarker or drug discovery worldwide.
Global Aptamers Market Trends:
The growing prevalence of life-threatening diseases, such as cancer, neurodegenerative, cardiovascular, and acquired immunodeficiency syndrome (AIDS), represents one of the key factors influencing the demand for new and effective detection assays based on aptamer therapy. Moreover, the advent of the chemical modification process to increase the nuclease resistance and enhance the therapeutic properties of aptamers is bolstering the market growth. The aptamers market growth can also be accredited to the rising number of research and development (R&D) activities undertaken for improving diagnostic devices and drugs and their carriers. Apart from this, as aptamers are chemically synthesized, which eliminates batch-to-batch variation and requires less time for development, their application is extensively increasing across the globe. Furthermore, private organizations are collaborating with academic institutes and research laboratories to introduce next-generation products and expand their existing market presence. This is anticipated to fuel the usage of aptamers in a wide range of medical therapies, as well as in the food and beverage (F&B) industry.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global aptamers market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type and application.
Breakup by Type:
Nucleic Acid
Peptide
Breakup by Application:
Diagnostics
Therapeutics
Research and Developments
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Aptagen LLC, Aptamer Group, Aptamer Sciences Inc., Aptus Biotech S.L., Base Pair Biotechnologies Inc., IBA GmbH, Kaneka Eurogentec S.A. (Kaneka Corporation), NeoVentures Biotechnology Inc., NOXXON Pharma, SomaLogic Inc., TriLink BioTechnologies LLC and Vivonics Inc.
Key Questions Answered in This Report:
- How has the global aptamers market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global aptamers market?
- What are the key regional markets?
- What is the breakup of the market based on the type?
- What is the breakup of the market based on the application?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global aptamers market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Aptamers Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Type
- 6.1 Nucleic Acid
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Peptide
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Application
- 7.1 Diagnostics
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Therapeutics
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Research and Developments
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Others
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
8 Market Breakup by Region
- 8.1 North America
- 8.1.1 United States
- 8.1.1.1 Market Trends
- 8.1.1.2 Market Forecast
- 8.1.2 Canada
- 8.1.2.1 Market Trends
- 8.1.2.2 Market Forecast
- 8.2 Asia-Pacific
- 8.2.1 China
- 8.2.1.1 Market Trends
- 8.2.1.2 Market Forecast
- 8.2.2 Japan
- 8.2.2.1 Market Trends
- 8.2.2.2 Market Forecast
- 8.2.3 India
- 8.2.3.1 Market Trends
- 8.2.3.2 Market Forecast
- 8.2.4 South Korea
- 8.2.4.1 Market Trends
- 8.2.4.2 Market Forecast
- 8.2.5 Australia
- 8.2.5.1 Market Trends
- 8.2.5.2 Market Forecast
- 8.2.6 Indonesia
- 8.2.6.1 Market Trends
- 8.2.6.2 Market Forecast
- 8.2.7 Others
- 8.2.7.1 Market Trends
- 8.2.7.2 Market Forecast
- 8.3 Europe
- 8.3.1 Germany
- 8.3.1.1 Market Trends
- 8.3.1.2 Market Forecast
- 8.3.2 France
- 8.3.2.1 Market Trends
- 8.3.2.2 Market Forecast
- 8.3.3 United Kingdom
- 8.3.3.1 Market Trends
- 8.3.3.2 Market Forecast
- 8.3.4 Italy
- 8.3.4.1 Market Trends
- 8.3.4.2 Market Forecast
- 8.3.5 Spain
- 8.3.5.1 Market Trends
- 8.3.5.2 Market Forecast
- 8.3.6 Russia
- 8.3.6.1 Market Trends
- 8.3.6.2 Market Forecast
- 8.3.7 Others
- 8.3.7.1 Market Trends
- 8.3.7.2 Market Forecast
- 8.4 Latin America
- 8.4.1 Brazil
- 8.4.1.1 Market Trends
- 8.4.1.2 Market Forecast
- 8.4.2 Mexico
- 8.4.2.1 Market Trends
- 8.4.2.2 Market Forecast
- 8.4.3 Others
- 8.4.3.1 Market Trends
- 8.4.3.2 Market Forecast
- 8.5 Middle East and Africa
- 8.5.1 Market Trends
- 8.5.2 Market Breakup by Country
- 8.5.3 Market Forecast
9 SWOT Analysis
- 9.1 Overview
- 9.2 Strengths
- 9.3 Weaknesses
- 9.4 Opportunities
- 9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
- 11.1 Overview
- 11.2 Bargaining Power of Buyers
- 11.3 Bargaining Power of Suppliers
- 11.4 Degree of Competition
- 11.5 Threat of New Entrants
- 11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
- 13.1 Market Structure
- 13.2 Key Players
- 13.3 Profiles of Key Players
- 13.3.1 Aptagen LLC
- 13.3.1.1 Company Overview
- 13.3.1.2 Product Portfolio
- 13.3.2 Aptamer Group
- 13.3.2.1 Company Overview
- 13.3.2.2 Product Portfolio
- 13.3.3 Aptamer Sciences Inc.
- 13.3.3.1 Company Overview
- 13.3.3.2 Product Portfolio
- 13.3.4 Aptus Biotech S.L.
- 13.3.4.1 Company Overview
- 13.3.4.2 Product Portfolio
- 13.3.5 Base Pair Biotechnologies Inc.
- 13.3.5.1 Company Overview
- 13.3.5.2 Product Portfolio
- 13.3.6 IBA GmbH
- 13.3.6.1 Company Overview
- 13.3.6.2 Product Portfolio
- 13.3.7 Kaneka Eurogentec S.A. (Kaneka Corporation)
- 13.3.7.1 Company Overview
- 13.3.7.2 Product Portfolio
- 13.3.8 NeoVentures Biotechnology Inc.
- 13.3.8.1 Company Overview
- 13.3.8.2 Product Portfolio
- 13.3.9 NOXXON Pharma
- 13.3.9.1 Company Overview
- 13.3.9.2 Product Portfolio
- 13.3.9.3 Financials
- 13.3.10 SomaLogic Inc.
- 13.3.10.1 Company Overview
- 13.3.10.2 Product Portfolio
- 13.3.11 TriLink BioTechnologies LLC
- 13.3.11.1 Company Overview
- 13.3.11.2 Product Portfolio
- 13.3.12 Vivonics Inc.
- 13.3.12.1 Company Overview
- 13.3.12.2 Product Portfolio
